For a metastatic neuroendocrine tumor patient who has experienced prolonged progression free survival, how would you approach surgical debulking?
Does the advent of more effective therapies like peptide receptor radioligand therapy (PRRT) and capecitabine and temozolomide (CAPTEM) dampen enthusiasm for debulking procedures? How aggressively should a patient be debulked?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic
Answered on · Updated on
This is a complicated answer (especially for me as a medical oncologist...). The main factors to consider are the tumor grade, tumor behavior, extent and location of metastases, patient's age and performance, and the location of the primary tumor.
For a patient with a G1/G2 pancreatic or SB NET with...
Join for free or sign in to see the full answer